Pinnacle Associates Ltd. boosted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 12.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 158,580 shares of the company’s stock after buying an additional 17,241 shares during the period. Pinnacle Associates Ltd.’s holdings in Teva Pharmaceutical Industries Limited were worth $5,268,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Advisory Services Network LLC purchased a new stake in shares of Teva Pharmaceutical Industries Limited during the first quarter worth about $163,000. ING Groep NV purchased a new stake in shares of Teva Pharmaceutical Industries Limited during the first quarter worth about $1,701,000. Grimes & Company Inc. raised its stake in shares of Teva Pharmaceutical Industries Limited by 27.3% in the first quarter. Grimes & Company Inc. now owns 49,880 shares of the company’s stock worth $1,601,000 after buying an additional 10,692 shares during the last quarter. Nwam LLC raised its stake in shares of Teva Pharmaceutical Industries Limited by 54.5% in the first quarter. Nwam LLC now owns 16,080 shares of the company’s stock worth $516,000 after buying an additional 5,674 shares during the last quarter. Finally, Pillar Pacific Capital Management LLC raised its stake in shares of Teva Pharmaceutical Industries Limited by 10.0% in the first quarter. Pillar Pacific Capital Management LLC now owns 91,688 shares of the company’s stock worth $2,942,000 after buying an additional 8,359 shares during the last quarter. 56.87% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 15.90 on Friday. The firm has a 50-day moving average of $23.15 and a 200 day moving average of $29.75. The firm’s market cap is $16.15 billion. Teva Pharmaceutical Industries Limited has a 1-year low of $15.32 and a 1-year high of $52.66.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. Teva Pharmaceutical Industries Limited’s revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the business earned $1.25 earnings per share. On average, analysts predict that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be issued a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a yield of 2.14%. The ex-dividend date of this dividend is Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is currently -15.36%.

COPYRIGHT VIOLATION NOTICE: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/09/03/teva-pharmaceutical-industries-limited-teva-shares-bought-by-pinnacle-associates-ltd.html.

A number of analysts have issued reports on TEVA shares. Maxim Group set a $35.00 target price on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research report on Thursday, May 11th. Deutsche Bank AG cut their target price on Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating on the stock in a research report on Friday, May 12th. Royal Bank Of Canada reissued an “outperform” rating and issued a $38.00 target price (down previously from $42.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Monday, May 15th. Credit Suisse Group reissued a “buy” rating and issued a $39.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, May 17th. Finally, Vetr raised Teva Pharmaceutical Industries Limited from a “buy” rating to a “strong-buy” rating and set a $34.25 target price on the stock in a research report on Wednesday, May 17th. Four research analysts have rated the stock with a sell rating, twenty have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $34.50.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.